The Rosenfeld group develops molecular diagnostic tools for cancer detection, characterisation and monitoring, to help make more informed treatment decisions. We focus on liquid biopsies, in which we analyse blood samples to detect and characterise cell-free circulating tumour DNA (ctDNA). We’ve shown that analysis of ctDNA can be used to identify tumour genomic alterations to select targeted therapies, and to identify patients with molecular residual disease (MRD) who remain at high risk after initial treatment and may benefit from further treatment. Current projects aim to develop assays for earlier detection of cancer in individuals at high risk, and simplified methods for cancer monitoring using few drops of blood.
In 2024, Professor Rosenfeld replaced Prof. Nick Lemoine as Director of the Barts Cancer Institute.